Careful monitoring of the long-term safety of factor D inhibitors and evaluating the risk of adverse or off-target effects will be paramount, especially because complement deficiencies are known to be associated with recurrent infections and an increased risk of autoimmune disorders (127). Here, LIF is linked to complement deficiency.